Dupilmab is a new treatment recently approved by the FDA. It is for the treatment of moderate-to-severe AD in adults whose AD symptoms are not well controlled with topical medications.
The purpose of this study is to determine how dupilmab affects the amount of bacteria on the skin, the skin's water loss and the immune symptom.
This study will enroll participants between 18-75 yrs old. All participants will have chronic moderate to severe atopic dermatitis.
How understandable was the trial content above?
Hard to understand
Easy to understand